Iovance Biotherapeutics, Inc. (IOVA) stock
IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.48−0.05 (-0.66%)
Close on Nov 18, 2026Market cap $3.39BP/E –Yield –
Iovance Biotherapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Iovance Biotherapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$264.18M. For fiscal 2025 it was -$302.41M. The highest annual figure on record is -$14.45K in fiscal 2009.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$302.41M | – |
| FY2024 | Dec 31, 2024 | -$352.98M | – |
| FY2023 | Dec 31, 2023 | -$361.82M | – |
| FY2022 | Dec 31, 2022 | -$292.76M | – |
| FY2021 | Dec 31, 2021 | -$227.94M | – |
| FY2020 | Dec 31, 2020 | -$205.13M | – |
| FY2019 | Dec 31, 2019 | -$158.89M | – |
| FY2018 | Dec 31, 2018 | -$101.25M | – |
| FY2017 | Dec 31, 2017 | -$78.71M | – |
| FY2016 | Dec 31, 2016 | -$32.67M | – |
| FY2015 | Dec 31, 2015 | -$18.38M | – |
| FY2014 | Dec 31, 2014 | -$8.63M | – |
| FY2013 | Dec 31, 2013 | -$3.66M | – |
| FY2012 | Dec 31, 2012 | -$2.24M | – |
| FY2011 | Dec 31, 2011 | -$6.19M | – |
| FY2010 | Dec 31, 2010 | -$620.81K | – |
| FY2009 | Dec 31, 2009 | -$14.45K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$60.84M | – |
| Q1 FY2026 | Mar 31, 2026 | -$72.07M | – |
| Q4 FY2025 | Dec 31, 2025 | -$52.57M | – |
| Q3 FY2025 | Sep 30, 2025 | -$78.70M | – |
| Q2 FY2025 | Jun 30, 2025 | -$67.45M | – |
| Q1 FY2025 | Mar 31, 2025 | -$103.69M | – |
| Q4 FY2024 | Dec 31, 2024 | -$73.30M | – |
| Q3 FY2024 | Sep 30, 2024 | -$58.97M | – |
| Q2 FY2024 | Jun 30, 2024 | -$98.43M | – |
| Q1 FY2024 | Mar 31, 2024 | -$122.28M | – |
| Q4 FY2023 | Dec 31, 2023 | -$83.97M | – |
| Q3 FY2023 | Sep 30, 2023 | -$84.08M | – |
| Q2 FY2023 | Jun 30, 2023 | -$93.95M | – |
| Q1 FY2023 | Mar 31, 2023 | -$99.82M | – |
| Q4 FY2022 | Dec 31, 2022 | -$77.67M | – |
| Q3 FY2022 | Sep 30, 2022 | -$63.65M | – |
| Q2 FY2022 | Jun 30, 2022 | -$77.64M | – |
| Q1 FY2022 | Mar 31, 2022 | -$73.80M | – |
| Q4 FY2021 | Dec 31, 2021 | -$53.85M | – |
| Q3 FY2021 | Sep 30, 2021 | -$57.69M | – |
| Q2 FY2021 | Jun 30, 2021 | -$54.01M | – |
| Q1 FY2021 | Mar 31, 2021 | -$62.39M | – |
| Q4 FY2020 | Dec 31, 2020 | -$62.69M | – |
| Q3 FY2020 | Sep 30, 2020 | -$40.52M | – |
| Q2 FY2020 | Jun 30, 2020 | -$36.64M | – |
| Q1 FY2020 | Mar 31, 2020 | -$65.29M | – |
| Q4 FY2019 | Dec 31, 2019 | -$53.82M | – |
| Q3 FY2019 | Sep 30, 2019 | -$42.18M | – |
| Q2 FY2019 | Jun 30, 2019 | -$33.80M | – |
| Q1 FY2019 | Mar 31, 2019 | -$29.09M | – |
| Q4 FY2018 | Dec 31, 2018 | -$31.55M | – |
| Q3 FY2018 | Sep 30, 2018 | -$27.93M | – |
| Q2 FY2018 | Jun 30, 2018 | -$23.92M | – |
| Q1 FY2018 | Mar 31, 2018 | -$17.85M | – |
| Q4 FY2017 | Dec 31, 2017 | -$20.96M | – |
| Q3 FY2017 | Sep 30, 2017 | -$21.45M | – |
| Q2 FY2017 | Jun 30, 2017 | -$17.50M | – |
| Q1 FY2017 | Mar 31, 2017 | -$18.80M | – |
| Q4 FY2016 | Dec 31, 2016 | -$12.16M | – |
| Q3 FY2016 | Sep 30, 2016 | -$12.21M | – |
See a number that looks wrong?